Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Go Back to All Clinical Trials

Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Brief description of study

The primary purpose of the study is to determine if accelerated BEP ((Bleomycin, Etoposide, and cisPlatin) is effective and tolerable for patients with advanced germ cell tumor compared to the standard treatment. We want to know if the accelerated chemotherapy using the same drugs is beneficial but not more toxic than the standard chemotherapy regimen. The accelerated chemotherapy is experimental.

Clinical Study Identifier: s18-01969

ClinicalTrials.gov Identifier: NCT02582697

Principal Investigator: Chana Glasser.

Other Investigators: Christeen Azmy, Lia Phillips, Sylwia Jasinski.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies